Search Results

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27.

Wiley (NYSE: WLY and WLYB), one of the world’s largest publishers and a global leader in research and learning, will host its Investor Update today at 10 am E.T. to discuss the company’s business and financial outlook.

Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer.

Scientific Industries, Inc. announced the appointment of John Nicols to the Board of Directors of SI and Chairman of its wholly, owned subsidiary, Scientific Bioprocessing Inc., effective March 4, 2024.

Wiley will release its second quarter 2024 results prior to market open on Wednesday, December 6, 2023.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications, announced the appointment of John Healy as General Counsel & Corporate Secretary.

ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of John Hohneker, M.D. to its Board of Directors.

Sonnet BioTherapeutics Holdings, Inc. announced today that preclinical data and clinical trial design from the study of SON-080.

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology.